Navigation Links
'First-in-human' drug for malignant glioma available in experimental trial
Date:2/15/2012

CINCINNATI -- The UC Cancer Institute is one of three centers internationally approved to test an experimental drug's safety and pharmacokinetics and also assess the clinical benefit against recurrent malignant glioma, an aggressive form of brain cancer.

The "first-in-human" phase-1 trial is expected to enroll up to 60 patients at clinical sites in the United States and Australia.

Led by Olivier Rixe, MD, PhD, this experimental drug trial uses antibody-drug conjugate (ADC) technology, a new drug delivery concept currently being investigated in the treatment of various cancers. ADC molecules consist of an antibody linked to a specific cytotoxic drug that is intended to target, bind and disperse only in malignant cells.

The experimental drug (called AMG 595) is intended to target a specific mutated cell receptor (EGFRvIII) which exists on the surface of tumor cells in up to 30 percent of patients with malignant gliomas. Preliminary studies in animals have shown that ADC molecules can effectively find these specific cancer cells, then enter them and release an active cytotoxic agent with the aim of killing the tumor cells while minimizing damage to the surrounding normal tissue.

"This allows us to use a highly cytotoxic drug targeted to the cancer cells in the brain based on a specific cellular marker," explains Rixe, John and Gladys Strauss Chair in Cancer Research at the UC College of Medicine and director of the Experimental Therapeutics/Phase 1 Clinical Trials Program. "Until recently, primary brain tumor patients have traditionally been excluded from phase-1 oncology studies, so finding drugs to effectively target and make real advances against this particular type of very aggressive cancer has been virtually impossible."

Patients who have failed first- and second-line therapies for malignant glioma may qualify to participate in this trial. Potential candidates will be screened for the EGFRvIII mutation using t
'/>"/>

Contact: Amanda Harper
amanda.harper@uc.edu
513-558-4657
University of Cincinnati Academic Health Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Cancer-targeting investigational nanoparticle receives FDA IND approval for first-in-human trial
2. Using Viagra to combat malignant melanoma
3. Elusive gene mutations found for malignant brain tumor
4. Agent selectively targets malignant B cells in chronic leukemia, study shows
5. Malignant brain tumors: Benefit of PET and PET/CT in the detection of recurrences is not assessable
6. Huge pelvi-abdominal malignant inflammatory myofibroblastic tumor
7. Novel RNA interference screening technique identifies possible path for malignant glioma treatment
8. CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
9. RTOG activates study to determine best treatment strategies for patients with glioma brain tumors
10. Photons vs. protons for treatment of spinal cord gliomas
11. Discordance among commercially-available diagnostics for latent TB infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 31, 2014 “United States Orthopedic Braces ... on the United States Orthopedic Braces and Supports market. The ... (in units) and average price data (in US dollars), within ... , Ankle Braces and Supports , ... and Supports. , Orthotics is a specialty within ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nationally recognized ... CNE, ANEF, who since September 2013 has served as ... became the new dean of the College of Nursing ... move marries her leadership of the NLN, as the ... the top-ranked academic nursing and research institutions in the ...
(Date:7/30/2014)... 2014 New changes are in store for ... move to a new facility. The official date of the ... moving soon. , MedX Pharmacy will be moving into a ... 77581. This is the old Wells Fargo building. The new ... include a drive thru for convenient drop-off and pick-up of ...
(Date:7/30/2014)... Serial entrepreneur, Paul Mata, spent the early part ... most people, in 2008 he suffered extreme financial hardship and ... Paul carefully studied the difference between people who have sustainable ... on the knowledge he acquired, he was able to use ... health, but also grow his clients' personal and financial assets ...
(Date:7/30/2014)... revitalized and expanded through a U.S.-funded effort that ... access and providing cutting-edge skills labs and other ... by participants of the $130 million Medical Education ... progress being made at the African institutions. Their ... by the journal Academic Medicine . Begun ...
Breaking Medicine News(10 mins):Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:MedX Pharmacy Relocates to New Facility 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3
... at 6th International Stem Cell Symposium Seoul, Korea - ... ... AlphaMed Press,publisher of the peer-reviewed journal STEM CELLS(R), announces that the,annual ... will be presented on June 20, 2008 in,Seoul, Korea. The US$10,000 award ...
... need, but sickest still going without, study finds , , TUESDAY, ... has resulted in some improvements for seniors but no real ... finds that Medicare beneficiaries are less likely to forego basic ... sickest patients are still skipping meds due to burdensome costs. ...
... winners from Indiana, South Carolina and Illinois are Runners-Up, ... a business niche when a friend had trouble finding ... the Year for turning his,idea into a multi-million dollar ... at the U.S. Small Business,Administration,s celebration of National Small ...
... for Policymakers, Consumers and the Media is First ... and Consumer Product,Issues, WASHINGTON, April 22 ... A Guide for,Consumers, Policymakers and the Media, the ... to provide current and scientifically accurate,information and resources ...
... greatest week after meds begin , , TUESDAY, April 22 ... are 60 percent more likely to develop pneumonia in the ... new study shows. , The risk is greatest during the ... decreases, say Dutch researchers. , "The risk of developing pneumonia ...
... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent ... care services and assisted living,companies, announced today that ... results following the market close on Wednesday, May ... Conference Call, Ensign invites current and prospective ...
Cached Medicine News:Health News:Stem Cells(R) and International Stem Cell Symposium Present Annual Stem Cells(R) Young Investigator Award 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 2Health News:Medicare Prescription Drug Benefit Shows Mixed Results 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 2Health News:Online Job Search Company from Virginia is National Small Business of the Year 3Health News:Online Job Search Company from Virginia is National Small Business of the Year 4Health News:Grocery Manufacturers Association Releases Science Policy Paper on Bisphenol A 2Health News:Antipsychotic Drugs Linked to Pneumonia in Elderly 2Health News:The Ensign Group Schedules 2008 First Quarter Earnings Call for Thursday, May 8, 2008 2
(Date:7/30/2014)... 30, 2014 In conjunction with DURECT Corporation,s ... results press release, you are invited to listen to ... the internet on Thursday, August 7, 2014 at 4:30 ... A live audio webcast of the presentation will be ... and clicking "Investor Relations."  If you are unable to ...
(Date:7/30/2014)... , July 30, 2014 PuraMed BioScience ... marketer of over-the-counter (OTC) medicinal and healthcare products, ... M name along with the name,s red ... with the trademarked name MigraPure ®  going ... of PuraMed,s homeopathic, natural migraine pain reliever will ...
(Date:7/30/2014)... /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... announced today that they have received CE Mark ... Velox CD™ provides a safe and predictable means ... The single size velox CD™ is indicated for ... to 8F.  Velox CD™ utilizes patented ...
Breaking Medicine Technology:DURECT Corporation Invites You to Join its Second Quarter 2014 Earnings Conference Call 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: